Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 180-194 , July 1997

A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection

  • Eleftherios C. Vamvakas

      Affiliations

    • Blood Transfusion Service, Massachusetts General Hospital, Boston, MA USA
    • Department of Pathology, Harvard Medical School, Boston, MA USA
    • Department of Pathology and Medicine, McMaster University, Ontario, Canada
    • Corresponding Author InformationAddress reprint requests to Eleftherios C. Vamvakas, MD, PhD, Blood Transfusion Service, GRJ 224, Massachusetts General Hospital, Boston, MA 02114.
    • ,
  • Morris A. Blajchman

      Affiliations

    • Blood Transfusion Service, Massachusetts General Hospital, Boston, MA USA
    • Department of Pathology, Harvard Medical School, Boston, MA USA
    • Department of Pathology and Medicine, McMaster University, Ontario, Canada

References 

  1. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5:253–259
  2. Francis DM. Relationship between blood transfusion and tumor behavior. Br J Surg. 1991;78:1420–1428
  3. Blumberg N, Heal JM. Effects of transfusion on immune function: cancer recurrence and infection. Arch Pathol Lab Med. 1994;118:371–379
  4. Vamvakas E. Perioperative blood transfusion and cancer recurrence: Meta-analysis for explanation. Transfusion. 1995;35:760–768
  5. Vamvakas E. Transfusion-associated cancer recurrence and infection: meta-analysis of the randomized controlled clinical trials. Transfusion. 1996;36:175–186
  6. Tartter PI. Blood transfusion and bacterial infections: clinical studies. In: Singal DP editors. Immunological Effects of Blood Transfusion. Boca Raton, FL: CRC Press; 1994;p. 111–126
  7. Vamvakas E, Moore SB. Blood transfusion and postoperative septic complications. Transfusion. 1994;34:714–727
  8. Duffy G, Neal KR. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomized and nonrandomized studies. Transfus Med. 1996;6:325–328
  9. Peters WR, Fry RD, Fleshman JW, et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum. 1989;32:749–753
  10. Busch MP, Collier A, Gernsheimer T, et al. The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion. 1996;36:854–859
  11. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703–1721
  12. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion. 1990;30:651–658
  13. Blajchman MA, Bordin JO. Mechanisms of transfusionrelated immunosuppression. Curr Opin Hematol. 1994;1:457–461
  14. Dzik S, Blajchman MA, Blumberg N, et al. Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang. 1996;70:187–194
  15. Gianotti L, Pyles T, Alexander JW, et al. Identification of the blood component responsible for increased susceptibility to gut-derived infection. Transfusion. 1993;33:458–465
  16. Singal DP. In: Singal DP editors. Immunological Effects of Blood Transfusion. Mechanisms of the blood transfusion effect. Boca Raton, FL: CRC Press; 1994;p. 155–185
  17. Goodarzi MO, Lee TH, Pallavicini MG, et al. Unusual kinetics of white cell clearance in transfused mice. Transfusion. 1995;35:145–149
  18. Jahnson S, Andersson M. Adverse effect of perioperative blood transfusion in patients with colorectal cancer. Eur J Surg. 1992;158:419–425
  19. Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. Transfusion. 1996;36:1000–1008
  20. Fernandez MC, Gottlieb M, Menitove JE. Blood transfusion and postoperative infection in orthopedic patients. Transfusion. 1992;32:318–322
  21. Vamvakas E, Moore SB, Cabanela M. Blood transfusion and septic complications after hip replacement surgery. Transfusion. 1995;35:150–156
  22. Schlesselman JJ. In: Case-Control Studies: Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982;p. 227–290
  23. Miettinen O. Confounding and effect-modification. Am J Epidemiol. 1974;100:350–353
  24. Klein HG. Immunomodulation caused by blood transfusion. In: Petz LD, Swisher SN, Kleinman S, Spence RK, Stauss RG editor. Clinical Practice of Transfusion Medicine. New York, NY: Churchill Livingstone; 1995;p. 59–69
  25. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg. 1992;79:513–516
  26. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet. 1993;342:1328–1333
  27. (letter) Busch ORC, Hop WCJ, Marquet RL, et al. Autologous blood and infections after colorectal surgery. Lancet. 1994;343:668–669
  28. Busch ORC, Hop WCJ, Hoynek van Papendrecht MAW, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–1376
  29. Houbiers JGA, Brand A, van de Watering LMG, et al. Randomized controlled trial comparing transfusion of leukocytedepleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:573–578
  30. Jensen LS, Kissmeyer-Nielsen P, Wolff B, et al. Randomized comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841–845
  31. (abstr SY3DI-06) van de Watering LMG, Houbiers JGA, Hermans J, et al. Leukocyte depletion reduces postoperative mortality in patients undergoing cardiac surgery. In: Proceedings of the 24th Congress of the International Society for Blood Transfusion. Makuhari, Japan. 1976;p. 37
  32. Marquet RL, Hoynck van Papendrecht MA, Busch OR, et al. Blood donation leads to a decrease in natural killer cell activity: a study in normal donors and cancer patients. Transfusion. 1993;33:368–373
  33. Nielsen HJ, Reimert CM, Pedersen AN, et al. Time-dependent, spontaneous release of white cell- and plateletderived bioactive substances from stored human blood. Transfusion. 1996;36:960–965
  34. Shau H, Golub SH. Modulation of natural killermediated lysis by red blood cells. Cell Immunol. 1988;116:60–72
  35. (letter), discussion Heiss MM, Mempel W, Jauch KW, et al. Leukocytedepleted or buffy coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:1429–1430Heiss MM, Mempel W, Jauch KW, et al. Leukocytedepleted or buffy coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:1430–1431
  36. Waymack JP, Robb E, Alexander JW. Effect of transfusion on immune function in a traumatized animal model: II. Effect on mortality rate following septic challenge. Arch Surg. 1987;122:935–939
  37. Waymack JP, Chance WT. Effect of blood transfusions on immune function: IV. Effect on tumor growth. J Surg Oncol. 1988;39:159–164
  38. Persijn GG, Cohen B, Lansbergen Q, et al. Retrospective and prospective studies on the effect of blood transfusion in renal transplantation in the Netherlands. Transplantation. 1979;28:396–401
  39. Hennekens CH, Buring JE. Statistical association and cause-effect relationships, in Epidemiology in Medicine. In: Boston, MA: Little, Brown; 1987;p. 30–53
  40. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. St. Louis, MO: Mosby-Year Book; 1995;
  41. Datta M. You cannot exclude the explanation you have not considered (facts, figures and fallacies). Lancet. 1993;342:345–347
  42. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585–612
  43. May GS, DeMets DL, Friedman LM, et al. The randomized clinical trial: Bias in the analysis. Circulation. 1981;64:669–673
  44. Passamani E. Clinical trials: Are they ethical?. N Engl J Med. 1991;324:1589–1591
  45. Hellman S, Hellman DS. Of mice but not men: Problems of the randomized clinical trial. N Engl J Med. 1991;324:1585–1589
  46. Birkmeyer JD, Goodnough LT, AuBuchon JP, et al. The cost-effectiveness of preoperative autologous blood donation for total hip and total knee replacement. Transfusion. 1993;33:544–551
  47. Etchason J, Petz L, Keeler E, et al. The cost-effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332:719–724
  48. Healy JC, Frankforter SA, Graves BK, et al. Preoperative autologous blood donation in total hip arthroplasty. A costeffectiveness analysis. Arch Pathol Lab Med. 1994;118:465–470
  49. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224–233
  50. Jenicek M. Meta-analysis in medicine: where we are and where we want to go. J Clin Epidemiol. 1989;42:35–44
  51. Goodman SN. Have you ever meta-analysis you didn't like?. Ann Intern Med. 1991;114:244–246
  52. Moher D, Olkin I. Meta-analysis of randomized controlled trials: a concern for standards. JAMA. 1995;274:1962–1964
  53. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450–455
  54. Huque MF. Experiences with meta-analysis in FDA submissions. Proc Biopharmaceutical Section Am Stat Assoc. 1988;2:28–33
  55. Dubey S. Regulatory considerations on meta-analysis and multicenter trials. Proc Biopharmaceutical Section Am Stat Assoc. 1988;2:18–27
  56. Stein RA. Meta-analysis from one FDA reviewer's perspective. Proc Biopharmaceutical Section Am Stat Assoc. 1988;2:34–38
  57. Felson DT. Bias in meta-analytic research. J Clin Epidemiol. 1992;45:885–892
  58. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989;81:107–114
  59. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J Royal Stat Soc A. 1988;151:419–463
  60. Dickersin K, Chan S, Chalmers TC, et al. Publication bias and clinical trials. Control Clin Trials. 1987;8:343–353
  61. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987;6:11–29
  62. Stewart LA, Parmar MKB. Meta-analysis of the literature or individual patient data: Is there a difference?. Lancet. 1993;341:418–422
  63. Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4:295–302
  64. The Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol. 1994;32:55–72
  65. Jeng FT, Scott JR, Burmeister LF. A comparison of meta-analytic results using literature vs individual patient data: paternal cell immunization for recurrent miscarriage. JAMA. 1995;274:830–836
  66. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ. 1991;303:884–893
  67. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 1992;339:1–15Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 1992;339:71–85
  68. Howe GR, Hirohata T, Hislop T, et al. Dietary factors and risk of breast cancer: Combined analysis of 12 case-control studies. J Natl Cancer Inst. 1992;82:561–569
  69. Longnecker MP, Martin-Moreno JM, Knekt P, et al. Serum α-tocopherol concentration in relation to subsequent colorectal cancer: Pooled data from five cohorts. J Natl Cancer Inst. 1990;84:430–435
  70. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: Evidence from the combined analysis of 13 case-controlled studies. J Natl Cancer Inst. 1992;84:1887–1896
  71. Clark DA, Gunby J, Daya S. The use of allogeneic leukocytes or IVIG for the treatment of patients with recurrent spontaneous abortion. Transfus Med Rev. 1997;11:85–94
  72. editorial Coulam CB, Clark DA. Immunotherapy for recurrent miscarriage. Am J Reprod Immunol. 1994;52:257–260
  73. O'Gorman TW, Woolson RF, Jones MP. A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial. Control Clin Trials. 1994;15:135–153
  74. Howard VJ, Grizzle J, Diener HC, et al. Comparison of multicenter study designs for investigation of carotid endarterectomy efficacy. Stroke. 1992;23:583–593
  75. Fleiss JL. Multicenter clinical trials: Bradford Hill's contributions and some subsequent developments. Stat Med. 1982;1:353–359
  76. Simchen E, Zucker D, Siegman IY, et al. Method for separating patient and procedural factors while analyzing interdepartmental differences in rates of surgical infections: The Israeli study of surgical infection in abdominal operations. J Clin Epidemiol. 1996;49:1003–1007
  77. Sakakibara T, Juji T. Posttransfusion graft-versus-host disease after open heart surgery. Lancet. 1986;2:687–691
  78. Bonser RS, Dave JR, John L, et al. Complement activation before, during, and after cardiopulmonary bypass. Eur J Cardiothorac Surg. 1990;4:291–296
  79. Videm V, Fosse E, Mollness TE, et al. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann thorac Surg. 1990;50:387–391
  80. (editorial) Clark WR. Prevention of anesthesia-induced immunosuppression: A novel strategy involving interferons. Anesthesiology. 1993;78:627–628
  81. (suppl) Bilfinger TV, Kushnerik V, Bundz S, et al. Evidence for morphine downregulating immunocytes during cardiopulmonary bypass in a porcine model. Int J Cardiol. 1996;53:39S–46S
  82. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I. Medical. Stat Med. 1989;8:441–454
  83. Miller JN, Colditz GA, Mosteller F. How study design affects outcomes in comparisons of therapy: II. Surgical. Stat Med. 1989;8:455–466
  84. (suppl 3) Meares EM. Current patterns in nosocomial urinary tract infections. Urology. 1991;37:9S–12S
  85. Collignon PJ. Intravascular catheter-associated sepsis: a common problem. The Australian Study on Intravascular Catheter-Associated Sepsis. Med J Aust. 1994;161:374–378
  86. Skerrett SJ, Niederman MS, Fein AM. Respiratory infections and acute lung injury in systemic illness. Clin Chest Med. 1989;10:469–502
  87. Hanson LC, Weber DJ, Rutala WA. Risk factors for nosocomial pneumonia in the elderly. Am J Med. 1992;92:161–166
  88. Craven DE, Knuches LM, Kilinsky V, et al. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis. 1986;133:792–796
  89. Dricks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317:1376–1382
  90. (suppl) Tryba M. The gastropulmonary route of infection—fact or fiction. Am J Med. 1991;91:135S–146S
  91. McFarland LV. Diarrhea acquired in the hospital. Gastroenterol Clin North Am. 1993;22:563–577
  92. Sawyer RG, Pruett TL. Wound infections. Surg Clin North Am. 1994;74:519–536
  93. (editorial) Andersen JW. Meta-analyses need new publication standards. J Clin Oncol. 1992;10:878–880
  94. In: Yusuf S,  Simon R,  Ellenberg S editor. Proceedings of “Methodologic Issues in Overviews of Randomized Clinical Trials.” Workshop sponsored by the National Heart Lung and Blood Institute and the National Cancer Institute. Stat Med. 6:1987;p. 217–409
  95. O'Rourke K, Detsky AS. Meta-analysis in medical research: Strong encouragement for higher quality in individual research efforts. J Clin Epidemiol. 1989;42:1021–1024
  96. Thompson SG, Pocock SJ. Can meta-analysis be trusted?. Lancet. 1991;338:1127–1130
  97. Cook TD, Cooper H, Cordray DS, et al. Meta-analysis for explanation: A casebook. New York, NY: Russell Sage Foundation; 1992;
  98. Ellenberg SS. Meta-analysis: the quantitative approach to research review. Sem Oncol. 1988;15:472–481
  99. Easterbrook PJ, Berlin JA, Copalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867–872
  100. In: Cooper H, Hedges LV editor. The handbook of research synthesis. New York, NY: Russell Sage Foundation; 1994;
  101. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748
  102. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  103. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: A critique. J Clin Epidemiol. 1991;44:127–139
  104. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  105. Chalmers TC, Levin H, Sacks HS, et al. Meta-analysis of clinical trials as a scientific discipline. I. Control of bias and comparison with large co-operative trials. Stat Med. 1987;6:315–325
  106. Peto R. Why do we need systematic overviews of randomized trials?. Stat Med. 1987;6:233–240
  107. Yusuf S. Obtaining medically meaningful answers from an overview of randomized clinical trials. Stat Med. 1987;6:281–286
  108. (letter) Smith SJ, Steinberg KK, Thacker SB. Methods for pooled analyses in epidemiologic studies. Epidemiology. 1994;5:381–382
  109. Olkin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol. 1995;48:133–146
  110. Chalmers I, Enkin M, Keirse MJNC. Preparing and updating systematic reviews of randomized controlled trials of health care. Milbank Q. 1993;71:411–437
  111. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res. 1993;2:173–192
  112. Thompson SG. Why sources of heterogencity in meta-analysis should be investigated. BMJ. 1994;309:1351–1355
  113. Blajchman MA. Editorial: Allogeneic blood transfusion, immunomodulation and postoperative bacterial infection: Do we have the answers yet?. Transfusion. 1997;37:121–125
  114. Centers for Disease Control. In: National Nosocomial Infections Surveillance System Information Packet. Atlanta, GA: U.S. Department of Health and Human Services; 1994;
  115. Boden WE. Meta-analysis in clinical reporting: Has a tool become a weapon?. Am J Cardiol. 1992;69:681–686
  116. Update 1992. III Ridker PM, Buring JE, Hennekens CH. Meta-analysis in cardiovascular disease: strengths and limitations. In: Braunwald E editors. Heat disease: A textbook of cardiovascular medicine. ed 4. Philadelphia, PA: W.B. Saunders; 1992;p. 54–64
  117. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized controlled trials: examples from the management of acute myocardial infarction. Ann Intern Med. 1995;123:873–877
  118. Wittes RE. Problems in the medical interpretation of overviews. Stat Med. 1987;6:269–276

PII: S0887-7963(97)80039-9

doi: 10.1053/tmrv.1997.0110180

Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 180-194 , July 1997

Article Tools